---

---

tags : Phase 1    exchanges : Nasdaq   

save search

---

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Published: 2023-03-28 (Crawled : 13:00) - biospace.com/
VKTX | $65.07 0.22% 0.15% 2.4M |

Health Technology

| 613.49% | O: 34.98% H: 25.83% C: 25.43%
LGND | $71.0 1.59% 1.38% 110K |

Health Technology

| 0.98% | O: -0.07% H: 5.37% C: 4.8%
vk2735 agonist therapeutics study phase 1

---

Plus Therapeutics Successfully Treats First Patient in Cohort 8 of ReSPECT-GBM Phase 1/2a Trial
Published: 2023-03-28 (Crawled : 12:00) - globenewswire.com
PSTV | News | $1.6 -1.84% -5.16% 8.5K |

Health Technology

| -61.16% | O: 1.97% H: 0.0% C: -2.68%
trial therapeutics plus phase 1

---

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735
Published: 2023-03-28 (Crawled : 11:00) - prnewswire.com
VKTX | $65.07 0.22% 0.15% 2.4M |

Health Technology

| 613.49% | O: 34.98% H: 25.83% C: 25.43%
LGND | $71.0 1.59% 1.38% 110K |

Health Technology

| 0.98% | O: -0.07% H: 5.37% C: 4.8%
vk2735 agonist trial therapeutics results endocrine disorders obesity phase 1

---

Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396
Published: 2023-03-28 (Crawled : 09:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21% |

Health Technology

| Email alert Add to watchlist
zp8396 pharma positive results phase 1

---

BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
Published: 2023-03-23 (Crawled : 13:00) - biospace.com/
BMY | $48.86 -0.27% 0.98% 14M |

Health Technology

| -27.33% | O: 0.52% H: 0.46% C: -0.9%
BBIO | $25.03 -1.69% -1.76% 1.5M |

Health Technology

| 94.94% | O: 0.62% H: 5.65% C: 5.11%
bbp-398 opdivo lung pharma cancer trial phase 1

---

Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373
Published: 2023-03-23 (Crawled : 12:20) - biospace.com/
ENVB | $0.934 4.08% 4.33% 180K |

Health Technology

| -47.01% | O: 2.56% H: 0.04% C: -5.0%
eb-373 study phase 1

---

FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder
Published: 2023-03-22 (Crawled : 13:00) - biospace.com/
HUGE | News | $0.4589 -2.15% -1.21% 280K |

Process Industries

| -67.75% | O: 0.65% H: 3.21% C: 0.0%
pharma candidate approval treatment trial potential phase 1 major depressive disorder

---

Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal MetastasesFirst data readout of Phase 1/Part A trial expected second half of 2023
Published: 2023-03-22 (Crawled : 12:00) - biospace.com/
PSTV | News | $1.6 -1.84% -5.16% 8.5K |

Health Technology

| -60.86% | O: 3.12% H: 1.39% C: 0.0%
expected readout trial therapeutics plus phase 1

---

Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal Metastases
Published: 2023-03-22 (Crawled : 11:00) - globenewswire.com
PSTV | News | $1.6 -1.84% -5.16% 8.5K |

Health Technology

| -60.86% | O: 3.12% H: 1.39% C: 0.0%
trial therapeutics plus phase 1

---

Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences
Published: 2023-03-20 (Crawled : 23:00) - biospace.com/
ALPN | $64.57 0.03% 0.03% 1.2M |

Health Technology

| 651.69% | O: 0.35% H: 1.39% C: -5.34%
alpn-303 sciences study phase 1

---

Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1
Published: 2023-03-20 (Crawled : 23:00) - biospace.com/
FUSN | $21.4 -0.09% -0.09% 260K |

Health Technology

| 415.66% | O: -2.17% H: 3.69% C: -1.48%
fpi-2059 tumors treatment pharmaceuticals therapy study phase 1

---

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia
Published: 2023-03-20 (Crawled : 12:20) - globenewswire.com
VAXX | $0.1326 -33.7% -53.85% 3M |

| -93.75% | O: -2.88% H: 2.72% C: 0.99%
vxx-401 vaccine trial hypercholesterolemia phase 1

---

Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting
Published: 2023-03-16 (Crawled : 23:00) - biospace.com/
ALPN | $64.57 0.03% 0.03% 1.2M |

Health Technology

| 703.11% | O: -1.37% H: 5.93% C: 5.04%
alpn-303 sciences meeting study phase 1

---

Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial
Published: 2023-03-16 (Crawled : 13:00) - globenewswire.com
DERM | $3.4 -3.96% -3.36% 60K |

| 141.13% | O: -4.96% H: 15.3% C: 10.07%
FBIO | $1.79 -1.11% -1.4% 120K |

Health Technology

| 148.03% | O: 2.54% H: 0.0% C: 0.0%
dfd-29 corporation treatment impact medical trial phase 1

---

Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
Published: 2023-03-16 (Crawled : 12:20) - biospace.com/
PYXS | $4.45 -1.11% -1.24% 230K |

Professional, Scientific, and T...

| 121.39% | O: 0.0% H: 7.46% C: 7.46%
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -34.78% | O: -0.55% H: 1.07% C: 0.77%
pyx-201 tumors trial phase 1

---

Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
Published: 2023-03-16 (Crawled : 12:20) - biospace.com/
ABUS | $2.75 -0.36% 350K |

Health Technology

| -9.24% | O: -0.33% H: 0.12% C: -2.65%
ab-161 trial phase 1

---

Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients
Published: 2023-03-15 (Crawled : 01:00) - biospace.com/
SNDX | $20.79 -0.86% -0.87% 370K |

Health Technology

| -7.93% | O: -1.59% H: 1.94% C: 0.36%
gment-101 pharmaceuticals leukemia phase 1

---

Skye Bioscience Receives Human Research Ethics Committee Approval to Start Multiple Ascending Dose Arm of Phase 1 Study of SBI-100 Ophthalmic Emulsion
Published: 2023-03-15 (Crawled : 15:20) - biospace.com/
SKYE | $12.85 -8.41% -9.23% 110K |

Transportation and Warehousing

| 49323.08% | O: -3.85% H: 8.0% C: 1.2%
sbi-100 arm approval bioscience research study phase 1

---

Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Published: 2023-03-14 (Crawled : 00:00) - biospace.com/
FNCTF | News | $11.16 1.13% -20.84% 0 |

Communications

| Email alert Add to watchlist
prtx007 research meeting association therapeutics cancer study phase 1

---

Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
Published: 2023-03-14 (Crawled : 22:00) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K |

Health Technology

| -91.3% | O: -44.77% H: 1.05% C: -9.73%
trials phase 1

---

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4253 179.25% 64.77% 210M |

Consumer Services

BOF | $2.08 77.78% 41.21% 110M |

ILAG | $0.54 12.27% 40.62% 3.7M |

LICN | $0.999 78.39% 40.49% 15M |

AMST | $3.4 70.0% 39.58% 70M |

Technology Services

MTC | $3.6 60.71% 38.04% 9.1M |

Technology Services

WIMI | $1.15 58.53% 36.92% 19M |

Technology Services

AIH | $0.458 14.5% 30.92% 91K |

Health Services

WHLM | $6.25 35.87% 28.46% 700K |

Commercial Services

MULN | News | $3.77 38.1% 27.78% 13M |

Information

---

Your saved searches

---